ReviewNeuroRx : the journal of the American Society for Experimental NeuroTherapeutics2005
Translational research in central nervous system drug discovery.
Review in NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of Placebo Response in Randomized Clinical Trials of Antipsychotic Drugs Using PANSS Focusing on Different Approaches to the Handling of Missing Data.Clinical drug investigation · 2018Pooled it
- Randomized, Blinded Pilot Testing of Nonconventional Stimulation Patterns and Shapes in Parkinson's Disease and Essential Tremor: Evidence for Further Evaluating Narrow and Biphasic Pulses.Neuromodulation : journal of the International Neuromodulation Society · 2016Trial
- Discovery-Driven Plasma Proteomics Identifies a Multi-Protein Signature for Amyloid PET Positivity: A Machine Learning Analysis of the Bio-Hermes Cohort.International journal of molecular sciences · 2026Article
- Interspecies Brain PBPK Modeling Platform to Predict Passive Transport through the Blood-Brain Barrier and Assess Target Site Disposition.Pharmaceutics · 2024Article
- Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model.Scientific reports · 2019Article
- Film interface for drug testing for delivery to cells in culture and in the brain.Acta biomaterialia · 2019Article
- A Simple Procedure for Creating Scalable Phenotypic Screening Assays in Human Neurons.Scientific reports · 2019Article
- Blood-Based Biomarkers of Quinpirole Pharmacology: Cluster-Based PK/PD and Metabolomics to Unravel the Underlying Dynamics in Rat Plasma and Brain.CPT: pharmacometrics & systems pharmacology · 2019Article
- Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of DBritish journal of pharmacology · 2018Article
- Commentary: Establishing zebrafish as a model to study the anxiolytic effects of scopolamine.Frontiers in pharmacology · 2018Article
- Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.The AAPS journal · 2017Review
- Studying human disease using human neurons.Brain research · 2017Review
- A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations.Pharmaceutical research · 2017Article
- ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis.Molecular neurodegeneration · 2016Article
- Influence of aripiprazole, risperidone, and amisulpride on sensory and sensorimotor gating in healthy 'low and high gating' humans and relation to psychometry.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Article
- The lonely mouse - single housing affects serotonergic signaling integrity measured by 8-OH-DPAT-induced hypothermia in male mice.PloS one · 2014Article
- Utility of CSF in translational neuroscience.Journal of pharmacokinetics and pharmacodynamics · 2013Review
- Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development.Journal of pharmacokinetics and pharmacodynamics · 2013Article
- Cell therapy: the final frontier for treatment of neurological diseases.CNS neuroscience & therapeutics · 2013Review
- Has the time come for predictive computer modeling in CNS drug discovery and development?CPT: pharmacometrics & systems pharmacology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Of all the therapeutic areas, diseases of the CNS provide the biggest challenges to translational research in this era of increased productivity and novel targets. Risk reduction by translational research incorporates the "learn" phase of the "learn and confirm" paradigm proposed over a decade ago. Like traditional drug discovery in vitro and in laboratory animals, it precedes the traditional phase 1-3 studies of drug development. The focus is on ameliorating the current failure rate in phase 2 and the delays resulting from suboptimal choices in four key areas: initial test subjects, dosing, sensitive and early detection of therapeutic effect, and recognition of differences between animal models and human disease. Implementation of new technologies is the key to success in this emerging endeavor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.